Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 331.5 INR 2.6% Market Closed
Market Cap: 398B INR
Have any thoughts about
Biocon Ltd?
Write Note

Biocon Ltd
Total Other Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biocon Ltd
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
Biocon Ltd
NSE:BIOCON
Total Other Income
â‚ą17.5B
CAGR 3-Years
67%
CAGR 5-Years
73%
CAGR 10-Years
40%
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Total Other Income
â‚ą26.1m
CAGR 3-Years
N/A
CAGR 5-Years
10%
CAGR 10-Years
0%
Transgene Biotek Ltd
BSE:526139
Total Other Income
â‚ą7.9m
CAGR 3-Years
44%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Total Other Income
â‚ą11.4m
CAGR 3-Years
-31%
CAGR 5-Years
-24%
CAGR 10-Years
-7%
Hester Biosciences Ltd
NSE:HESTERBIO
Total Other Income
â‚ą82m
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Panacea Biotec Ltd
NSE:PANACEABIO
Total Other Income
â‚ą235.2m
CAGR 3-Years
25%
CAGR 5-Years
29%
CAGR 10-Years
N/A
No Stocks Found

Biocon Ltd
Glance View

Market Cap
398B INR
Industry
Biotechnology

Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.

BIOCON Intrinsic Value
455.48 INR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Biocon Ltd's Total Other Income?
Total Other Income
17.5B INR

Based on the financial report for Sep 30, 2024, Biocon Ltd's Total Other Income amounts to 17.5B INR.

What is Biocon Ltd's Total Other Income growth rate?
Total Other Income CAGR 10Y
40%

Over the last year, the Total Other Income growth was 261%. The average annual Total Other Income growth rates for Biocon Ltd have been 67% over the past three years , 73% over the past five years , and 40% over the past ten years .

Back to Top